The DOI matches its Crossref record; 283 of the 283 references it cites were found in a registry or an index.
“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway
Open accessAbstract
Janus tyrosine kinase (JAK) family of proteins have been identified as crucial proteins in signal transduction initiated by a wide range of membrane receptors. Among the proteins in this family JAK2 has been associated with important downstream proteins, including signal transducers and activators of transcription (STATs), which in turn regulate the expression of a variety of proteins involved in induction or prevention of apoptosis. Therefore, the JAK/STAT signaling axis plays a major role in the proliferation and survival of different cancer cells, and may even be involved in resistance mechanisms against molecularly targeted drugs. Despite extensive research focused on the protein structure and mechanisms of activation of JAKs, and signal transduction through these proteins, their importance in cancer initiation and progression seem to be underestimated. This manuscript is an attempt to highlight the role of JAK proteins in cancer biology, the most recent developments in targeting JAKs, and the central role they play in intracellular cross-talks with other signaling cascades.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–283 of 283
Wang, J., Wang, X., Hussain, S., Zheng, Y., Sanjabi, S., Ouaaz, F., & Beg, A. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6777 · Cited by 94
IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis
Fontaine, R. H., Cases, O., Lelièvre, V., Mesplès, B., Renauld, J., Loron, G., Degos, V., Dournaud, P., Baud, O., & Gressèns, P. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.79 · Cited by 93
Zheng, Q., Han, L., Dong, Y., Tian, J., Huang, W., Liu, Z., Jia, X., Jiang, T., Zhang, J., Li, X., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou046 · Cited by 93
Roy, B., Bhattacharjee, A., Xu, B., Ford, D., Maizel, A., & Cathcart, M. K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.3.580 · Cited by 93
Stat5B Shuttles Between Cytoplasm and Nucleus in a Cytokine-Dependent and -Independent Manner
Zeng, R., Aoki, Y., Yoshida, M., Arai, K., & Watanabe, S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4567 · Cited by 92
Reasons for breast cancer heterogeneity
Bertucci, F., & Birnbaum, D. (2008) · Journal of Biology · doi:10.1186/jbiol67 · Cited by 90
Eyking, A., Ey, B., Rünzi, M., Roig, A. I., Reis, H., Schmid, K. W., Gerken, G., Podolsky, D. K., & Cario, E. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.043 · Cited by 86
The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer
Zhu, X., & Zhou, W. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00159 · Cited by 84
JAK2 the future: therapeutic strategies for JAK-dependent malignancies
LaFave, L. M., & Levine, R. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.08.005 · Cited by 84
Zhu, T., Goh, E. L. K., & Lobie, P. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10682 · Cited by 84
The role of constitutively active Stat6 in leukemia and lymphoma
Bruns, H. A., & Kaplan, M. H. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.005 · Cited by 82
Interleukin-3–Induced Activation of the JAK/STAT Pathway Is Prolonged by Proteasome Inhibitors
Callus, B. A., & Mathey-Prévôt, B. (1998) · Blood · doi:10.1182/blood.v91.9.3182 · Cited by 81
Stein, B. L., Oh, S. T., Berenzon, D. P., Hobbs, G. S., Kremyanskaya, M., Rampal, R. K., Abboud, C. N., Adler, K., Heaney, M. L., Jabbour, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6474 · Cited by 81
Oh, S. T., & Gotlib, J. (2010) · Expert Review of Hematology · doi:10.1586/ehm.10.28 · Cited by 78
Gao, L., Xu, D.-Q., Wen, L., Zhang, X., Shao, Y., & Zhao, X. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00053.x · Cited by 77
Expression of Interleukin 11 and Its Receptor and Their Prognostic Value in Human Breast Cancer
Hanavadi, S., Martin, T. A., Watkins, G., Mansel, R. E., & Jiang, W. G. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.05.028 · Cited by 75
TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients
Wang, C., Cao, S., Yan, Y., Ying, Q., Jiang, T., Xu, K., & Wu, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-415 · Cited by 75
Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer
Rao (2009) · International Journal of Oncology · doi:10.3892/ijo_00000249 · Cited by 75
Yue, P., Lopez‐Tapia, F., Paladino, D., Li, Y., Chen, C., Namanja, A. T., Hilliard, T. S., Chen, Y., Tius, M. A., & Turkson, J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3558 · Cited by 74
Yammani, R. R., Long, D. L., & Loeser, R. F. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24295 · Cited by 73
TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting
Herrmann, A., Cherryholmes, G. A., Schroeder, A., Phallen, J. A., Alizadeh, D., Xin, H., Wang, T., Lee, H., Lahtz, C., Swiderski, P. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1151 · Cited by 72
Interleukin-7 (IL-7) and IL-7 receptor (IL-7R) signalling complex in human solid tumours.
Al-Rawi, M. A. A., Mansel, R. E., & Jiang, W. G. (2003) · PubMed · doi:10.14670/hh-18.911 · Cited by 72
Hayashi, T., Kobayashi, Y., Kohsaka, S., & Sano, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209434 · Cited by 71
Ueno, H., Sasaki, K., Miyagawa, K., Honda, H., Mitani, K., Yazaki, Y., & Hirai, H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.13.8739 · Cited by 71
Biology of IL-27 and its Role in the Host Immunity against Mycobacterium Tuberculosis
Abdalla, A. E., Li, Q., Xie, L., & Xie, J. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10464 · Cited by 71
Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells
Huang, J., Chuang, L., Guh, J., Huang, Y.-J., & Hsu, M.-S. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00020.2007 · Cited by 71
Pezet, A., Buteau, H., Kelly, P. A., & Edery, M. (1997) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(97)00063-4 · Cited by 70
Growth hormone receptor modulators
Birzniece, V., Sata, A., & Ho, K. K. Y. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9089-x · Cited by 70
Molecular Mechanism for SHP2 in Promoting HER2-induced Signaling and Transformation
Zhou, X., & Agazie, Y. M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900020200 · Cited by 68
Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer Models
Sun, Y., Moretti, L., Giacalone, N. J., Schleicher, S. M., Speirs, C. K., Carbone, D. P., & Lü, B. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820d9d11 · Cited by 67
Sachsenmaier, C., Sadowski, H. B., & Cooper, J. A. (1999) · Oncogene · doi:10.1038/sj.onc.1202694 · Cited by 67
G-protein-independent Activation of Tyk2 by the Platelet-activating Factor Receptor*
Lukashova, V., Asselin, C., Krolewski, J., Rola-Pleszczynski, M., & Stankova, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100720200 · Cited by 65
Ali, M., Sayeski, P. P., & Bernstein, K. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m908931199 · Cited by 65
Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis
Masri, A. A., & Gendler, S. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208738 · Cited by 62
Extracellular signal-dependent nuclear import of STAT3 is mediated by various importin αs
Ushijima, R., Sakaguchi, N., Kano, A., Maruyama, A., Miyamoto, Y., Sekimoto, T., Yoneda, Y., Ogino, K., & Tachibana, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.063 · Cited by 61
STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma
Zhang, Q., Zhang, C., He, J., Guo, Q., Hu, D., Yang, X., Wang, J., Kang, Y., She, R., Wang, Z., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-2823-y · Cited by 61
The role of JAK2 inhibitors in MPNs 7 years after approval
Passamonti, F., & Maffioli, M. (2018) · Blood · doi:10.1182/blood-2018-01-791491 · Cited by 60
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside
Bruno, B., Giaccone, L., Rotta, M., Anderson, K. C., & Boccadoro, M. (2005) · Leukemia · doi:10.1038/sj.leu.2403905 · Cited by 59
Cao, Z., Zheng, Q., Li, G., Hu, X., Feng, S., Xu, G., & Zhang, K.-Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120921 · Cited by 57
Masamune, A. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i22.3385 · Cited by 56
Role of the STAT1-SH2 Domain and STAT2 in the Activation and Nuclear Translocation of STAT1
Mowen, K., & David, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30073 · Cited by 53 · cited 1×
“STAT1 forms a heterodimer with phosphorylated STAT2, and IFN-regulatory factor 9, and is transported into nucleus to bind to IFN-stimulated response element (ISRE) in promoters of the responsive genes (167, 168).”
BackgroundEgwuagu, C. E., Li, W., Yu, C.-R., Lin, M. C. M., Chan, C.-C., Nakamura, T., & Chepelinsky, A. B. (2006) · Oncogene · doi:10.1038/sj.onc.1209402 · Cited by 53
Burke, F., Smith, P., Crompton, M. R., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690491 · Cited by 53
Shen, L., Guangshun, Z., Lou, Z., Xu, G., & Zhang, G. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1548-4 · Cited by 53
Trevino, J. G., Gray, M. J., Nawrocki, S. T., Summy, J. M., Lesslie, D. P., Evans, D. B., Sawyer, T. K., Shakespeare, W. C., Watowich, S. S., Chiao, P. J., et al. (2006) · Angiogenesis · doi:10.1007/s10456-006-9038-9 · Cited by 52
Impaired development of human Th1 cells in patients with deficient expression of STAT4
Chang, H., Han, L., Goswami, R., Nguyen, E., Pelloso, D., Robertson, M. J., & Kaplan, M. H. (2009) · Blood · doi:10.1182/blood-2008-09-179820 · Cited by 52
Erythropoietin and Interleukin-2 Activate Distinct JAK Kinase Family Members
Barber, D. L., & D’Andrea, A. D. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6506 · Cited by 52
Jak1–STAT3 Signals Are Essential Effectors of the USP6/TRE17 Oncogene in Tumorigenesis
Quick, L., Young, R., Henrich, I. C., Wang, X., Asmann, Y. W., Oliveira, A. M., & Chou, M. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2391 · Cited by 51
Estrogens Regulate the Hepatic Effects of Growth Hormone, a Hormonal Interplay with Multiple Fates
Fernández‐Pérez, L., Guerra, B., Díaz-Chico, J. C., & Flores‐Morales, A. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00066 · Cited by 50
Verma, N. K., Davies, A. M., Long, A., Kelleher, D. P., & Volkov, Y. (2010) · Cellular & Molecular Biology Letters · doi:10.2478/s11658-010-0008-2 · Cited by 50
Jak2 Tyrosine Kinase: A True Jak of All Trades?
Sandberg, E. M., Wallace, T. A., Godeny, M. D., VonDerLinden, D., & Sayeski, P. P. (2004) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:41:2:207 · Cited by 50
A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis
Colaizzo, D., Amitrano, L., Tiscia, G. L., Grandone, E., Guardascione, M. A., & Margaglione, M. (2007) · Blood · doi:10.1182/blood-2007-05-092502 · Cited by 48
Chan, S. R., Rickert, C. G., Vermi, W., Sheehan, K. C. F., Arthur, C. D., Allen, J. A., White, J. M., Archambault, J. M., Lonardi, S., McDevitt, T. M., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.116 · Cited by 47
Bjorge, J. D., Pang, A., Funnell, M., Chen, K. Y., Diaz, R., Magliocco, A. M., & Fujita, D. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019309 · Cited by 46
Musumeci, F., Greco, C., Giacchello, I., Fallacara, A. L., Ibrahim, M. M., Grossi, G., Brullo, C., & Schenone, S. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180327093502 · Cited by 46
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
Verstovšek, S., Tam, C. S. L., Wadleigh, M., Sokol, L., Smith, C. C., Bui, L. A., Song, C., Clary, D. O., Olszynski, P., Cortes, J. E., et al. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.12.006 · Cited by 45
Swiatek-Machado, K., Mieczkowski, J., Ellert‐Miklaszewska, A., Świerk, P., Fokt, I., Szymański, S., Skóra, S., Szeja, W., Grynkiewicz, G., Lesyng, B., et al. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20083 · Cited by 43
Nucleic acid-based approaches to STAT inhibition
Sen, M., & Grandis, J. R. (2012) · JAK-STAT · doi:10.4161/jkst.22312 · Cited by 42
Seavey, M. M., Lu, L. D., Stump, K. L., Wallace, N. H., Hockeimer, W., O’Kane, T. M., Ruggeri, B., & Dobrzański, P. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0951 · Cited by 42
Narla, R. K., Liu, X.-P., Myers, D. E., & Uckun, F. M. (1998) · PubMed · Cited by 41
Hay, A. E., Murugesan, A., DiPasquale, A. M., Kouroukis, T., Sandhu, I., Kukreti, V., Bahlis, N. J., Lategan, J., Reece, D. E., Lyons, J. F., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1091927 · Cited by 41
Liu, C., Gao, F., Li, B., Mitchel, R. E. J., Liu, X., Js, L., Zhao, L., & Cai, J. (2011) · Leukemia · doi:10.1038/leu.2011.113 · Cited by 39
Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression
Yokogami, K., Yamashita, S., & Takeshima, H. (2012) · Brain Tumor Pathology · doi:10.1007/s10014-012-0122-0 · Cited by 39
Velloso, L. A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00098-4 · Cited by 38
Akahane, K., Li, Z., Etchin, J., Berezovskaya, A., Gjini, E., Masse, C. E., Miao, W., Rocnik, J. L., Kapeller, R., Greenwood, J. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14563 · Cited by 37
Oufkir, T., & Vaillancourt, C. (2011) · Placenta · doi:10.1016/j.placenta.2011.09.005 · Cited by 36
STAT nuclear translocation: potential for pharmacological intervention
Meyer, T., & Vinkemeier, U. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.10.1355 · Cited by 36
Baricitinib for the treatment of rheumatoid arthritis
Kubo, S., Nakayamada, S., & Tanaka, Y. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1214576 · Cited by 36
The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response
Wagner, M. A., & Siddiqui, M. A. Q. (2012) · JAK-STAT · doi:10.4161/jkst.20702 · Cited by 35
Vosshenrich, C. A. J., & Santo, J. P. D. (2002) · Current Biology · doi:10.1016/s0960-9822(02)01286-1 · Cited by 34
Sun, Y., Qiao, L., Xia, H. H., Lin, M. C. M., Zou, B., Yuan, Y., Zhu, S., Gu, Q., Cheung, T. K., Kung, H. F., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.10.014 · Cited by 32
Bao, L., Alexander, J. B., Shi, V. Y., Mohan, G. C., & Chan, L. S. (2014) · Immunology · doi:10.1111/imm.12339 · Cited by 31
Li, S., Xia, X., Mellieon, F. M., Liu, J., & Steele, S. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.022 · Cited by 29
AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
Yang, J., Ikezoe, T., Nishioka, C., Furihata, M., & Yokoyama, A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0416 · Cited by 27
Amini, Z., Martinez-Moczygemba, M., & Huston, D. P. (2012) · Current Allergy and Asthma Reports · doi:10.1007/s11882-012-0290-3 · Cited by 26
Kawakami, K., Kawakami, M., & Puri, R. K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.137.3.2 · Cited by 22
Role of insulin receptor substrate‐2 in interleukin‐9‐dependent proliferation
Demoulin, J., Grasso, L., Atkins, J. M., Stevens, M., Louahed, J., Levitt, R. C., Nicolaides, N. C., & Renauld, J. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02059-7 · Cited by 21
Ni, B., Chen, S., Xie, H., & Ma, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089111 · Cited by 21
A unique role for Stat5 in recovery from acute anemia
Longmore, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27988 · Cited by 18
Wu, Q., Ma, M., Fu, L. N., Zhu, Y., Liu, Y., Cao, J., Zhou, P., Li, Z., Zeng, L.-Y., Li, F., et al. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.05.120 · Cited by 13
Saki, N., Shirzad, R., Rahim, F., & Malehi, A. S. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1618-1 · Cited by 12
Lee, J. J., Simborio, H. L. T., Reyes, A. W. B., Hop, H. T., Arayan, L. T., Lee, H.-J., Min, W., Her, M., Rhee, M. H., Watarai, M., et al. (2016) · BMC Microbiology · doi:10.1186/s12866-016-0685-8 · Cited by 8
Alderton, G. K. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3499 · Cited by 7
Cited by
Signaling pathways in rheumatoid arthritis: implications for targeted therapy
Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
Kaur, S., Bansal, Y., Kumar, R., & Bansal, G. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115327 · Cited by 449
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
Qin, J.-J., Yan, L., Zhang, J., & Zhang, W.-D. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 396
Zhu, H., Jian, Z., Zhong, Y., Ye, Y., Zhang, Y., Hu, X., Pu, B., Gu, L., & Xiong, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714943 · Cited by 370
Metadata
- Authors
- Bousoik, E., & Montazeri Aliabadi, H.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2018-07-31
- Volume
- 8
- Pages
- 287-287
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W2886980930
- Cited by
- 376
- References
- 283
- FWCI
- 12.30
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.